MCH拮抗活性を有する新規カルボキサミド化合物、これらの化合物を含む医薬組成物及びそれらの製造方法

Japanese Patent JP2006507246

A

Carboxamides (I), their tautomers, diastereoisomers, enantiomers, mixtures and salts are new. Carboxamides of formula (I), their tautomers, diastereoisomers, enantiomers, mixtures and salts are new, including compounds where hydrogen atoms on carboxy or nitrogen are replaced by a group that can be cleaved in vivo. R1 and R2 = hydrogen, 1-8C alkyl or 3-7C cycloalkyl, both optionally substituted by R11, or phenyl, optionally substituted by one or more R12 and/or nitro, R1+R2 = 2-8C alkylene (particularly having one or two CH2 replaced by CH=N or CH=CH; or having one or two CH2 replaced by oxygen, sulfur, CO, C(=CH2) or NR13, provided two heteroatoms are not adjacent; having one or more hydrogen replaced by R14; or is substituted by 1 or 2 Cy, bound through single or double bonds, a single C, forming a spiro system, two adjacent C and/or N, forming a fused bicyclic system, or 3 or more C and/or N atoms, forming a bridged bicyclic system; R3 = hydrogen, 1-6C alkyl, 3-7C cycloalkyl, 3-7C cycloalkyl(1-4C)alkyl or 2-6C alkyl substituted by 1-6C alkoxy or amino, optionally substituted by 1 or 2 1-3C alkyl; X = single bond or 1-8C alkylene (particularly having 1 or 2 CH2 replaced by CH=CH, ethynyl, oxygen, S(O)x, CO or NR4, provided heteroatoms are not connected; and/or having 1 or 2 C substituted by hydroxy, omega-(hydroxy or 1-3C alkoxy) alkyl and/or 1-3C alkoxy and/or 1-6C alkyl; X+R1 or Z+R3 = heterocycle; Z = 1-4C alkylene (particularly two adjacent C may be linked by another 1-4C alkylene; one CH2 may be replaced by oxygen or NR5, or 1 or 2 C may be substituted by hydroxy, omega-(hydroxy or 1-3C alkoxy) alkyl, 1-3C alkoxy or amino(1-3C)alkyl (optionally N substituted by 1 or 2 1-3C alkyl) and/or 1 or 2 1-6C alkyl); A+Y' = carbocyclic or heterocyclic groups (Cy), and R1 with Y may form a heterocyclic group fused on Y and/or R3 with Y may form a saturated or partially unsaturated heterocycle fused on Y; A+R3 (i.e. -N(R3)CO-A-) = moiety of formula (i); Q = CR6R7, CR6=CR7, N=CR8, N=N, CONR9, CR8=N or CO; L1-L3 = R20; B' = Cy, bonded through a C atom of the carbocyclic part or fused phenyl or pyridyl or through N or C atom of the heterocyclic part; W' = single bond, oxygen, 1-4C alkylene(oxy), 2-4C alkenylene, oxy(1-4C)alkylene, 1-3C alkyleneoxy(1-3C)alkylene, (1-3C alkyl)imino, (1-3C alkyl)imino(1-4C)alkylene or 1-4C alkylene(1-3C alkyl)imino; W'-B' = W'=B' (i.e.(oxy)alkylene or alkyleneoxyalkylene); Cy = saturated 3-7 membered carbocycle; unsaturated 5-7 membered carbocycle; phenyl; saturated 4-7 membered or unsaturated 5-7 membered heterocycle containing nitrogen, oxygen or sulfur as heteroatoms; (un)saturated 5-7 membered heterocycle with 2 or more N or with one N and one O or S; aromatic 5 or 6 membered heterocycle with one or more of N, O and/or S; the 5-7 membered rings may be fused to a phenyl or pyridyl ring and/or have one CH2 replaced by CO, C(=CH2), SO or SO2; and the 6-7 membered rings may exist as bridged systems, containing imino (optionally substituted by 1-3C alkyl) or methylene, optionally substituted by 1 or 2 1-3C alkyl; and all optionally substituted on 1 or more C by R20 (also by nitro for phenyl groups) and/or by 1 or more R21 on N; R4, R5 and R16 = hydrogen, 3-7C cycloalkyl (Cyl), Cyl(1-3C)alkyl, 4-7C cycloalkenyl (Cya), Cya(1-3C)alkyl, omega-(hydroxy or 1-3C alkoxy)2-3C alkyl, or amino(1-6C)alkyl, optionally N-substituted by 1 or 2 1-3C alkyl; R6-R9 = hydrogen, 1-6C alkyl or omega-(hydroxy or 1-3C alkoxy)alkyl; also (except for R9) halo; R11 = R15O, R15OCO, R16R17N, R18R19NCO or Cy; R12 and R20 = halo, hydroxy, cyano, 1-4C alkyl, Cyl, hydroxy(1-3C)alkyl, R22-(1-3C)alkyl or R22; R13 and R17 = R16, also phenyl, phenyl(1-3C)alkyl, dioxolan-2-yl, 1-3C alkylcarbonyl, carboxy(1-3C)alkyl, 1-3C alkylcarbonylamino(2-3C)alkyl, 1-3C alkylsulfonyl or 1-3C alkylsulfonylamino(2-3C)alkyl; R14 = halo, 1-6C alkyl, R15O, R15OCO, R16R17N, R18R19NCO, R15O- or R15-OCO- (1-3C)alkyl, R16R17N(1-3C)alkyl, R18R19NCO(1-3C)alkyl or Cy-(1-3C)alkyl; R15 = hydrogen, 1-4C alkyl,

Lehmann Linz Torsten
Stenkamp Dirk
Renter martin
Wieland Heike Andrea
Rudolph Claus
Mueller Stefan Georg
Lots Ralph El Her
Arlund Kirsten
Rustenberger Philip

JP2004535098A

March 02, 2006

August 16, 2003

Click for automatic bibliography generation  

Boehringer Ingelheim Pharma Gesellshaft Mitt Beschlenktel Haftung Und Company Comandito Gesellshaft

C07C233/78; A61K31/166; A61K31/195; A61K31/223; A61K31/397; A61K31/40; A61K31/4025; A61K31/4035; A61K31/407; A61K31/435; A61K31/438; A61K31/439; A61K31/4439; A61K31/4453; A61K31/454; A61K31/4545; A61K31/455; A61K31/46; A61K31/472; A61K31/495; A61K31/496; A61K31/517; A61K31/53; A61K31/5377; A61K31/55; A61P3/04; A61P3/10; A61P9/04; A61P9/10; A61P9/12; A61P13/12; A61P15/00; A61P15/02; A61P19/02; A61P25/00; A61P25/02; A61P25/22; A61P25/24; A61P25/28; A61P35/00; A61P43/00; C07D205/04; C07D207/09; C07D207/14; C07D207/16; C07D207/20; C07D209/14; C07D209/44; C07D209/46; C07D209/48; C07D211/14; C07D211/16; C07D211/28; C07D211/34; C07D211/52; C07D211/64; C07D213/40; C07D213/56; C07D213/74; C07D213/81; C07D217/04; C07D221/20; C07D221/24; C07D221/26; C07D223/16; C07D239/90; C07D239/91; C07D239/96; C07D241/04; C07D249/18; C07D253/08; C07D295/073; C07D295/096; C07D295/12; C07D295/135; C07D295/14; C07D295/185; C07D295/192; C07D295/215; C07D307/54; C07D333/24; C07D333/28; C07D333/68; C07D401/04; C07D401/06; C07D401/10; C07D401/12; C07D401/14; C07D403/10; C07D407/10; C07D451/02; C07D451/04; C07D471/08; C07D471/10; C07D487/04; C07D487/10

Sadao Kumakura
Nobuo Ogawa
Atsushi Hakoda
Kenji Asai
Koji Hirayama

Previous Patent: ４−（３，３−ジハロ−アリルオキシ）フェノキシアルキル誘導体

Next Patent: ＣＯＸ−２阻害性ピリジン誘導体